Department of Medicine, Queen Mary Hospital, University of Hong Kong, Pokfulam, Hong Kong.
Am J Kidney Dis. 2011 May;57(5):760-72. doi: 10.1053/j.ajkd.2011.01.014. Epub 2011 Feb 23.
Heart failure is one of the most frequent cardiac complications in patients with end-stage renal disease receiving long-term hemodialysis or peritoneal dialysis and is associated strongly with a poor prognosis. Despite the significant morbidity and mortality associated with heart failure, there are very limited therapeutic options proved to prevent and treat heart failure in dialysis patients. This limitation largely reflects the paucity of adequately powered prospective randomized clinical trials that have examined the efficacy of different therapeutic options in long-term dialysis patients with heart failure. In this article, the second in a series discussing the management of heart failure in dialysis patients, current therapeutic options for heart failure in the maintenance dialysis population are reviewed and potential novel therapeutic options are discussed.
心力衰竭是接受长期血液透析或腹膜透析的终末期肾病患者最常见的心脏并发症之一,与预后不良密切相关。尽管心力衰竭相关的发病率和死亡率很高,但目前可用的治疗方法非常有限,无法预防和治疗透析患者的心力衰竭。这种局限性在很大程度上反映了在长期接受透析治疗且伴有心力衰竭的患者中,检查不同治疗选择疗效的大型前瞻性随机临床试验非常有限。本文是讨论透析患者心力衰竭管理的系列文章中的第二篇,主要回顾了维持性透析人群心力衰竭的现有治疗选择,并讨论了潜在的新型治疗选择。